[go: up one dir, main page]

MX2008008152A - Compuestos heterociclicos biciclicos. - Google Patents

Compuestos heterociclicos biciclicos.

Info

Publication number
MX2008008152A
MX2008008152A MX2008008152A MX2008008152A MX2008008152A MX 2008008152 A MX2008008152 A MX 2008008152A MX 2008008152 A MX2008008152 A MX 2008008152A MX 2008008152 A MX2008008152 A MX 2008008152A MX 2008008152 A MX2008008152 A MX 2008008152A
Authority
MX
Mexico
Prior art keywords
bicyclic heteroaryl
heteroaryl compounds
compounds
preparation
general formula
Prior art date
Application number
MX2008008152A
Other languages
English (en)
Inventor
Dong ZOU
Wei-Sheng Huang
R Mathew Thomas
Yihan Wang
Xiaotian Zhu
William C Shakespeare
Rajeswari Sundaramoorthi
Chester A Metcalf Iii
David C Dalgarno
Tomi K Sawyer
Jan Antoinette C Romero
Jiwei Qi
Original Assignee
Ariad Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38218600&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2008008152(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ariad Pharma Inc filed Critical Ariad Pharma Inc
Publication of MX2008008152A publication Critical patent/MX2008008152A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La invención se refiere a compuestos de la fórmula general (I): (ver fórmula (I)) en la que los grupos variables son como se definen aquí, y a su preparación y uso.
MX2008008152A 2005-12-23 2006-12-22 Compuestos heterociclicos biciclicos. MX2008008152A (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US75400005P 2005-12-23 2005-12-23
US75396205P 2005-12-23 2005-12-23
US75608906P 2006-01-03 2006-01-03
US79847206P 2006-05-08 2006-05-08
US83319106P 2006-07-25 2006-07-25
PCT/US2006/048758 WO2007075869A2 (en) 2005-12-23 2006-12-22 Bicyclic heteroaryl compounds

Publications (1)

Publication Number Publication Date
MX2008008152A true MX2008008152A (es) 2008-09-12

Family

ID=38218600

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2013004842A MX343042B (es) 2005-12-23 2006-12-22 Compuestos heteroarilicos biciclicos.
MX2008008152A MX2008008152A (es) 2005-12-23 2006-12-22 Compuestos heterociclicos biciclicos.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2013004842A MX343042B (es) 2005-12-23 2006-12-22 Compuestos heteroarilicos biciclicos.

Country Status (21)

Country Link
US (10) US8114874B2 (es)
EP (4) EP3417912B1 (es)
JP (3) JP5200939B2 (es)
KR (1) KR101436303B1 (es)
CN (1) CN103044432B (es)
AU (1) AU2006331673B2 (es)
CA (1) CA2634923C (es)
CY (3) CY1113907T1 (es)
DK (2) DK2495016T3 (es)
EA (2) EA034598B1 (es)
ES (2) ES2761180T3 (es)
FR (1) FR13C0069I2 (es)
HU (2) HUE047422T2 (es)
IL (2) IL191938A (es)
LT (1) LT2495016T (es)
LU (1) LU92327I2 (es)
MX (2) MX343042B (es)
PL (2) PL1973545T3 (es)
PT (2) PT2495016T (es)
SI (1) SI2495016T1 (es)
WO (1) WO2007075869A2 (es)

Families Citing this family (105)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007021937A2 (en) 2005-08-11 2007-02-22 Ariad Pharmaceuticals, Inc. Unsaturated heterocyclic derivatives
CA2634923C (en) * 2005-12-23 2015-05-05 Ariad Pharmaceuticals, Inc. Acetylenic bicyclic heteroaryl compounds useful as kinase inhibitors
AU2007249924B2 (en) 2006-05-08 2013-07-04 Ariad Pharmaceuticals, Inc. Acetylenic heteroaryl compounds
KR101441365B1 (ko) * 2006-05-08 2014-09-18 어리어드 파마슈티칼스, 인코포레이티드 모노시클릭 헤테로아릴 화합물
JP2010500365A (ja) 2006-08-07 2010-01-07 インサイト・コーポレイション キナーゼ阻害剤としてのトリアゾロトリアジン
US8558002B2 (en) 2006-11-16 2013-10-15 Allergan, Inc. Sulfoximines as kinase inhibitors
US8143410B2 (en) 2006-11-16 2012-03-27 Allergan, Inc. Kinase inhibitors
BRPI0718895A2 (pt) 2006-11-16 2013-12-10 Allergan Inc Composto de sulfoximina e uso do referido composto
JP5572388B2 (ja) 2006-11-22 2014-08-13 インサイト・コーポレイション キナーゼ阻害剤としてのイミダゾトリアジンおよびイミダゾピリミジン
EP2070929A1 (en) * 2007-12-11 2009-06-17 Bayer Schering Pharma Aktiengesellschaft Alkynylaryl compounds and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same
JP6022158B2 (ja) 2008-05-21 2016-11-09 インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ ２−フルオロ−Ｎ−メチル−４−［７−（キノリン−６−イル−メチル）−イミダゾ［１，２−ｂ］［１，２，４］トリアジン−２−イル］ベンズアミドの塩及びそれを調製することに関する方法
FR2933981A1 (fr) * 2008-07-18 2010-01-22 Sanofi Aventis NOUVEAUX DERIVES IMIDAZO°1,2-a!PYRIDINE, LEUR PROCEDE DE PREPARATION, LEUR APPLICATION A TITRE DE MEDICAMENTS, COMPOSITIONS PHARMACEUTIQUES ET NOUVELLE UTILISATION NOTAMMENT COMME INHIBITEURS DE MET
CA2732520A1 (en) * 2008-08-05 2010-02-11 Merck Sharp & Dohme Corp. Therapeutic compounds
CA2743449C (en) 2008-11-12 2016-10-18 Ariad Pharmaceuticals, Inc. Pyrazinopyrazines and derivatives as kinase inhibitors
AU2010313152A1 (en) * 2009-10-30 2012-04-19 Ariad Pharmaceuticals, Inc. Methods and compositions for treating cancer
US9180127B2 (en) 2009-12-29 2015-11-10 Dana-Farber Cancer Institute, Inc. Type II Raf kinase inhibitors
ES2608329T3 (es) * 2010-02-03 2017-04-07 Incyte Holdings Corporation Imidazo[1,2-b][1,2,4]triazinas como inhibidores de c-Met
US8846671B2 (en) 2010-07-01 2014-09-30 Guangzhou Institute Of Biomedicine And Health, Chinese Academy Of Sciences Heterocyclic alkynyl benzene compounds and medical compositions and uses thereof
CN101885722B (zh) * 2010-07-01 2013-07-24 中国科学院广州生物医药与健康研究院 杂环炔苯类化合物及其药用组合物和应用
KR101892574B1 (ko) * 2011-01-21 2018-08-28 썬 파마 어드밴스트 리서치 컴패니 리미티드 디아릴아세틸렌 히드라지드 함유 티로신 키나제 억제제
WO2012127030A1 (en) * 2011-03-23 2012-09-27 Proteosys Ag Arylpiperazines as neuroprotective agents
US20140045826A1 (en) * 2011-04-07 2014-02-13 Ariad Pharmaceuticals, Inc. Methods and compositions for treating neurodegenerative diseases
KR20140022062A (ko) * 2011-04-07 2014-02-21 어리어드 파마슈티칼스, 인코포레이티드 파킨슨병을 치료하기 위한 방법 및 조성물
RU2477723C2 (ru) * 2011-06-16 2013-03-20 Общество С Ограниченной Ответственностью "Фьюжн Фарма" Ингибиторы протеинкиназ (варианты), их применение для лечения онкологических заболеваний и фармацевтическая композиция на их основе
US9382239B2 (en) 2011-11-17 2016-07-05 Dana-Farber Cancer Institute, Inc. Inhibitors of c-Jun-N-terminal kinase (JNK)
US20150105377A1 (en) * 2012-04-25 2015-04-16 Ariad Pharmaceuticals, Inc. Methods and Compositions for RAF Kinase Mediated Diseases
US9254288B2 (en) * 2012-05-07 2016-02-09 The Translational Genomics Research Institute Susceptibility of tumors to tyrosine kinase inhibitors and treatment thereof
CN103420977B (zh) * 2012-05-16 2016-06-22 上海医药集团股份有限公司 具有抗肿瘤活性的乙炔衍生物
US8859553B2 (en) * 2012-07-30 2014-10-14 Astar Biotech Llc Protein kinase inhibitors
WO2014028595A1 (en) * 2012-08-14 2014-02-20 Concert Pharmaceuticals, Inc. Deuterated ponatinib
CN103664787B (zh) * 2012-09-17 2015-09-09 南京圣和药业股份有限公司 炔杂芳环化合物及其应用
WO2014063068A1 (en) 2012-10-18 2014-04-24 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
US10000483B2 (en) 2012-10-19 2018-06-19 Dana-Farber Cancer Institute, Inc. Bone marrow on X chromosome kinase (BMX) inhibitors and uses thereof
USRE48175E1 (en) 2012-10-19 2020-08-25 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged small molecules as inducers of protein degradation
TWI574962B (zh) 2012-11-14 2017-03-21 加拓科學公司 作爲ｐｉ３激酶調節劑的芳雜環化合物及其使用方法和用途
CN103848829B (zh) 2012-11-28 2017-04-12 南京圣和药业股份有限公司 杂芳基炔烃化合物及其应用
CA3167093A1 (en) 2012-12-12 2014-06-12 Ariad Pharmaceuticals, Inc. Crystalline form c of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-n-{4-[(4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl}benzamide mono hydrochloride
EP2968276A4 (en) * 2013-03-15 2017-02-15 President and Fellows of Harvard College Hybrid necroptosis inhibitors
US20140343282A1 (en) 2013-05-16 2014-11-20 Apicore, Llc Processes for making ponatinib and intermediates thereof
AU2014286047B2 (en) * 2013-07-04 2018-02-08 Sandoz Ag Crystalline forms of ponatinib hydrochloride
CN104341416B (zh) * 2013-07-31 2017-03-29 南京圣和药业股份有限公司 蛋白酪氨酸激酶抑制剂及其应用
GB2518873A (en) * 2013-10-03 2015-04-08 Agency Science Tech & Res Bicyclic alkyne derivatives and uses thereof
EP3057955B1 (en) 2013-10-18 2018-04-11 Syros Pharmaceuticals, Inc. Heteroaromatic compounds useful for the treatment of prolferative diseases
AU2014337044A1 (en) 2013-10-18 2016-05-05 Dana-Farber Cancer Institute, Inc. Polycyclic inhibitors of cyclin-dependent kinase 7 (CDK7)
US9636340B2 (en) 2013-11-12 2017-05-02 Ayyappan K. Rajasekaran Kinase inhibitors
CN104650086A (zh) * 2013-11-22 2015-05-27 天津市汉康医药生物技术有限公司 盐酸帕纳替尼化合物
WO2015085971A1 (en) 2013-12-09 2015-06-18 Zentiva, K.S. Hydrobromide salt of 3-(2-imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-n-[4-[(4-methyl-1-piperazinyl)methyl]-3-(trifluoromethyl)phenyl] benzamide
WO2015085973A1 (en) 2013-12-09 2015-06-18 Zentiva, K.S. Modifications of 3-(2-imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-n-[4-[(4-methyl-1-piperazinyl)methyl]-3-(trifluoromethyl)phenyl] benzamide hydrochloride salt
WO2015085972A1 (en) 2013-12-09 2015-06-18 Zentiva, K.S. NOVEL SALTS OF 3-(2-IMIDAZO[1,2-b]PYRIDAZIN-3-YLETHYNYL)-4-METHYL-N-[4-[(4-METHYL- 1-PIPERAZINYL)METHYL]-3-(TRIFLUOROMETHYL)PHENYL] BENZAMIDE
CN104496995A (zh) * 2014-01-06 2015-04-08 广东东阳光药业有限公司 制备3-乙炔基咪唑并[1,2-b]哒嗪的方法
GB2522226A (en) * 2014-01-17 2015-07-22 Agency Science Tech & Res Heteroaryl alkyne derivatives and uses thereof
WO2015164604A1 (en) 2014-04-23 2015-10-29 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged janus kinase inhibitors and uses thereof
US10017477B2 (en) 2014-04-23 2018-07-10 Dana-Farber Cancer Institute, Inc. Janus kinase inhibitors and uses thereof
EA201692371A1 (ru) 2014-06-06 2017-04-28 Натко Фарма Лимитед 1h-1,8-нафтиридин-2-оны в качестве антипролиферативных соединений
HUE046008T2 (hu) 2014-07-17 2020-02-28 Sunshine Lake Pharma Co Ltd I-(5-terc-butil)-izoxazol-3-il)-3-(4-((feniI)-etinil)-fenil)-kabamid származékok, valamint az ezekkel rokon vegyületek FLT-3 inhibitorokként rák kezelésére
WO2016059220A1 (en) 2014-10-16 2016-04-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Tcr-activating agents for use in the treatment of t-all
US10870651B2 (en) 2014-12-23 2020-12-22 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (CDK7)
CN105837575B (zh) * 2015-01-13 2019-01-15 四川大学 3-乙炔基吡唑并嘧啶衍生物及其制备方法和用途
US10550121B2 (en) 2015-03-27 2020-02-04 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases
CN106167491A (zh) * 2015-05-19 2016-11-30 重庆大学 一种有效抑制肺癌转移的化合物及其应用
US9988389B2 (en) 2015-06-11 2018-06-05 Apicore Us Llc Processes for making ponatinib and intermediates thereof
EP3307728A4 (en) 2015-06-12 2019-07-17 Dana Farber Cancer Institute, Inc. COMBINATION THERAPY OF TRANSCRIPTION INHIBITORS AND CHINESE INHIBITORS
JP2018531916A (ja) * 2015-09-09 2018-11-01 ウォーレン シー． ラウ， 新規のｆｙｎキナーゼ阻害剤の方法、組成物、及び使用
WO2017044858A2 (en) 2015-09-09 2017-03-16 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases
BR112018067538A2 (pt) 2016-03-03 2019-02-05 Univ Cornell inibidores de ire1-alfa de pequenas moléculas
WO2017156350A1 (en) 2016-03-09 2017-09-14 K-Gen, Inc. Methods of cancer treatment
CN109641893B (zh) * 2016-06-20 2021-07-20 大邱庆北尖端医疗产业振兴财团 新的咪唑并吡啶衍生物及其制备方法和用途
WO2018002958A1 (en) 2016-06-30 2018-01-04 Sun Pharma Advanced Research Company Limited Novel hydrazide containing compounds as btk inhibitors
US20210006178A1 (en) * 2016-09-29 2021-01-07 Transportation Ip Holdings, Llc Harmonic distortion reduction system for converters connected to a common bus
US10221184B2 (en) 2017-01-20 2019-03-05 Apicore Us Llc Polymorphs of ponatinib hydrochloride
CA3056348A1 (en) 2017-03-15 2018-09-20 Sun Pharma Advanced Research Company Limited Novel amorphous dispersion of 4-methyl-3-quinolin-3-ylethynyl-benzoic acid n'-(2-chloro-6-methyl-benzoyl) hydrazide
US11273126B2 (en) 2017-03-15 2022-03-15 Sun Pharma Advanced Research Company Limited Amorphous dispersion of cyclopropanecarboxylic acid (5-{5-[N′-(2-chloro-6-methylbenzoyl) hydrazinocarbonyl]-2-methyl-phenylethynyl}-pyridin-2-yl) amide
CA3067271A1 (en) 2017-06-20 2018-12-27 Apotex Inc. Crystalline forms of ponatinib hydrochloride
JP7024960B2 (ja) * 2017-10-04 2022-02-24 国立大学法人京都大学 Ｂｃｒ－Ａｂｌタンパク質イメージング用分子プローブ
WO2019246479A1 (en) 2018-06-22 2019-12-26 Johnson Matthey Public Limited Company Form of ponatinib
CA3099763A1 (en) 2018-06-25 2020-01-02 Dana-Farber Cancer Institute, Inc. Taire family kinase inhibitors and uses thereof
CN110194772B (zh) * 2018-07-02 2022-04-05 深圳市塔吉瑞生物医药有限公司 用于抑制蛋白激酶活性的炔基（杂）芳环类化合物
EP3808746B1 (en) * 2018-07-17 2023-08-02 Shenzhen TargetRx, Inc. N-[3-[2-[8-[(1h-pyrazol-4-yl)amino]imidazo[1,2-a]pyrazin-3-yl]ethynyl]phenyl]-benzamide derivatives and related compounds as protein kinase inhibitors for the treatment of cancer
EP3849985A4 (en) * 2018-09-12 2022-05-18 Purdue Research Foundation ALKYNYL NICOTINAMIDE COMPOUNDS AS KINASE INHIBITORS
US11427591B2 (en) 2018-10-17 2022-08-30 Insilico Medicine Ip Limited Kinase inhibitors
JP2022515705A (ja) 2018-11-01 2022-02-22 サイロス ファーマシューティカルズ， インコーポレイテッド サイクリン依存性キナーゼ７（ｃｄｋ７）の非共有結合性阻害剤を用いてバイオマーカーにより特定された患者におけるがんを処置する方法
EP3876939A4 (en) 2018-11-07 2022-08-10 Dana-Farber Cancer Institute, Inc. Benzothiazole derivatives and 7-aza-benzothiazole derivatives as janus kinase 2 inhibitors and uses thereof
US12509455B2 (en) 2018-11-07 2025-12-30 Dana-Farber Cancer Institute, Inc. Imidazopyridine derivatives and aza-imidazopyridine derivatives as Janus kinase 2 inhibitors and uses thereof
EP3876930A4 (en) 2018-11-07 2022-07-20 Dana-Farber Cancer Institute, Inc. BENZIMIDAZOLE DERIVATIVES AND AZA-BENZIMIDAZOLE DERIVATIVES AS JANUS KINASE 2 INHIBITORS AND USES THEREOF
EP3903828A4 (en) 2018-12-21 2022-10-05 Daiichi Sankyo Company, Limited ANTIBODY-DRUG CONJUGATE AND KINAS INHIBITOR COMBINATION
JP7660063B2 (ja) 2018-12-28 2025-04-10 ダナ－ファーバー キャンサー インスティテュート， インコーポレイテッド サイクリン依存性キナーゼ７のインヒビターおよびそれらの使用
WO2020214999A1 (en) * 2019-04-17 2020-10-22 Emory University Abelson non-tyrosine kinase compounds for the treatment of neurodegenerative diseases
US12398142B2 (en) 2019-04-17 2025-08-26 Emory University Abelson non-tyrosine kinase compounds for the treatment of neurodegenerative diseases
WO2020223235A1 (en) 2019-04-29 2020-11-05 Incyte Corporation Mini-tablet dosage forms of ponatinib
KR102205619B1 (ko) 2019-06-12 2021-01-21 한국과학기술연구원 신규한 인다졸 유도체 화합물 및 이를 포함하는 암의 예방, 개선 또는 치료용 약학 조성물
CN111004240B (zh) * 2019-12-13 2020-12-01 山东铂源药业有限公司 一种泊那替尼中间体3-乙炔基咪唑并[1,2-b]哒嗪的合成方法
CN115996917B (zh) 2020-05-06 2025-10-28 艾捷斯治疗公司 作为jak2抑制剂的6-杂芳基氧基苯并咪唑和氮杂苯并咪唑
WO2021228983A1 (en) 2020-05-13 2021-11-18 INSERM (Institut National de la Santé et de la Recherche Médicale) A pharmaceutical composition comprising an arsenic compound, an inductor of type-1 ifn and a protein kinase inhibitor for treating cancer
US20230219934A1 (en) * 2020-06-24 2023-07-13 Purdue Research Foundation 2,3-disubstituted pyrido[3,4-b]pyrazine-containing compounds as kinase inhibitors
WO2022053130A1 (en) 2020-09-09 2022-03-17 Sid Alex Group, S.R.O. Antago-mir-155 for treatment of v-src, c-src-tyrosine kinase-induced cancers
EP4267574B1 (en) 2020-12-23 2025-04-23 Ajax Therapeutics, Inc. 6-heteroaryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors
US20220289756A1 (en) * 2021-03-11 2022-09-15 Wai Kit Pang Compounds and compositions as inhibitors of protein kinases
CN112778207A (zh) * 2021-03-19 2021-05-11 海南鑫开源医药科技有限公司 一种盐酸尼洛替尼原料药杂质及其制备方法
JP7793217B2 (ja) * 2021-04-13 2026-01-05 シェンツェン ニューデル バイオテック カンパニー リミテッド アルキニルフェニルベンズアミド化合物およびその使用
US20240199626A1 (en) * 2021-04-19 2024-06-20 Oregon Health & Science University Compounds with improved cardiac safety for the treatment of cancer and neurodegenerative disorders
CA3237696A1 (en) 2021-11-08 2023-05-11 Progentos Therapeutics, Inc. Platelet-derived growth factor receptor (pdgfr) alpha inhibitors and uses thereof
TW202325289A (zh) 2021-11-09 2023-07-01 美商雅捷可斯治療公司 Ｊａｋ２抑制劑之形式及組合物
EP4430042A1 (en) 2021-11-09 2024-09-18 Ajax Therapeutics, Inc. 6-he tero aryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors
AR131605A1 (es) * 2023-01-13 2025-04-09 Shenzhen Newdel Biotech Co Ltd Sales y formas cristalinas del compuesto a, métodos de preparación y sus usos
WO2025253311A1 (en) 2024-06-04 2025-12-11 Hetero Labs Limited 1,2-dicarboxamide compounds as kinase inhibitors

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4736866B1 (en) 1984-06-22 1988-04-12 Transgenic non-human mammals
US5099057A (en) 1987-10-19 1992-03-24 The Dow Chemical Company Process for the preparation of ar-amino-para-arenediols
US5099067A (en) 1988-08-05 1992-03-24 Northwestern University Use of ammonium formate as a hydrogen transfer reagent for reduction of chiral nitro compounds with retention of configuration
US5175383A (en) 1989-02-17 1992-12-29 President And Fellows Of Harvard College Animal model for benign prostatic disease
ATE117690T1 (de) 1990-03-01 1995-02-15 Takeda Chemical Industries Ltd Imidazopyridazine, ihre herstellung und verwendung.
EP0824533B1 (de) 1995-05-09 2001-11-14 Basf Aktiengesellschaft PYRAZOLO- 1,5a]-PYRIMIDINE, VERFAHREN ZU IHRER HERSTELLUNG UND IHRE VERWENDUNG
GB9823871D0 (en) * 1998-10-30 1998-12-23 Pharmacia & Upjohn Spa 2-Amino-thiazole derivatives, process for their preparation, and their use as antitumour agents
DE19948434A1 (de) 1999-10-08 2001-06-07 Gruenenthal Gmbh Substanzbibliothek enthaltend bicyclische Imidazo-5-amine und/oder bicyclische Imidazo-3-amine
CN1177840C (zh) 1999-11-08 2004-12-01 先灵公司 制备n-(4-羟基苯基)-n′-(4′-氨基苯基)-哌嗪的方法
US6420365B1 (en) 2000-01-18 2002-07-16 Neurogen Corporation Imidazopyridines and related derivatives as selective modulators of bradykinin B2 receptors
HN2001000008A (es) * 2000-01-21 2003-12-11 Inc Agouron Pharmaceuticals Compuesto de amida y composiciones farmaceuticas para inhibir proteinquinasas, y su modo de empleo
DE10019714A1 (de) 2000-04-20 2002-01-10 Gruenenthal Gmbh Salze von bicyclischen, N-acylierten Imidazo-3-aminen und Imidazo-5-aminen
DE10021246A1 (de) 2000-04-25 2001-10-31 Schering Ag Substituierte Benzoesäureamide und deren Verwendung als Arzneimittel
HUP0301801A2 (hu) 2000-07-14 2003-09-29 Bristol-Myers Squibb Pharma Company Imidazo[1,2-a]pirazin-származékok és az ezeket tartalmazó gyógyszerkészítmények
DE10050663A1 (de) 2000-10-13 2002-04-18 Gruenenthal Gmbh Verwendung von substituierten Imidazo[1,2-a]pyridin-, -pyrimidin- und pyrazin-3-yl-amin-Derivaten zur Herstellung von Medikamenten zur NOS-Inhibierung
SE0100568D0 (sv) 2001-02-20 2001-02-20 Astrazeneca Ab Compounds
DE10117183A1 (de) 2001-04-05 2002-10-10 Gruenenthal Gmbh Verwendung von substituierten Imidazo[1,2-a]-pyridinverbindungen als Arzneimittel
DE10117184A1 (de) 2001-04-05 2002-10-17 Gruenenthal Gmbh Substituierte Imidazol[1,2-a]-pyridin-3-yl-amid- und -aminverbindungen
ATE317850T1 (de) 2001-05-30 2006-03-15 Novartis Pharma Gmbh 2-((n-(2-amino-3-(heteroaryl- oder - aryl)propionyl)aminoacyl)amino)- alkylboronsäurederivate
AU2002350105A1 (en) 2001-06-21 2003-01-08 Ariad Pharmaceuticals, Inc. Novel quinazolines and uses thereof
IL159811A0 (en) 2001-07-13 2004-06-20 Neurogen Corp Heteroaryl substituted fused bicyclic heteroaryl compounds as gabaa receptor ligands
ATE362933T1 (de) 2001-09-04 2007-06-15 Sumitomo Chemical Co Imidazo(1,2-a)pyrimidine und diese enthaltende fungizidzusammensetzungen
EP1478648B1 (en) 2002-02-01 2014-04-30 ARIAD Pharmaceuticals, Inc. Phosphorus-containing compounds and uses thereof
KR20050008691A (ko) 2002-04-19 2005-01-21 셀룰러 지노믹스 아이엔씨 이미다조[1,2-ａ]피라진-8-일 아민, 그의 제조방법 및사용방법
CN1658854A (zh) * 2002-06-05 2005-08-24 株式会社医药分子设计研究所 免疫关联蛋白激酶抑制剂
AU2003252509A1 (en) 2002-07-29 2004-02-16 Sumitomo Chemical Takeda Agro Company, Limited NOVEL PROCESS FOR PRODUCING IMIDAZO(1,2-b)PYRIDAZINE DERIVATIVE
WO2004023972A2 (en) 2002-09-11 2004-03-25 Becton, Dickinson And Company Monitoring blood glucose including convenient display of measurement values ________________________________________________________
DE10246890A1 (de) 2002-10-08 2004-04-22 Grünenthal GmbH Substituierte C-Imidazo[1,2-alpyridin-3-yl-methylamine
DE10247269A1 (de) 2002-10-10 2004-04-22 Grünenthal GmbH Substituierte C-Imidazo[1,2-a]pyridin-3-yl-methylamine
AR041992A1 (es) * 2002-11-06 2005-06-08 Smithkline Beecham Corp Compuesto de piridinil benzoheterociclico, composicion farmaceutica que lo comprende y su uso para prepararla
GB0230089D0 (en) * 2002-12-24 2003-01-29 Astrazeneca Ab Therapeutic agents
EP1615697A2 (en) 2003-04-11 2006-01-18 Novo Nordisk A/S New pyrazolo[1,5-a] pyrimidine derivatives and pharmaceutical use thereof
DK1684763T3 (da) 2003-09-24 2008-09-01 Wyeth Corp 6-Aryl-7-halogen-imidazo(1,2-a)pyrimidiner som anticancermiddel
WO2005047290A2 (en) 2003-11-11 2005-05-26 Cellular Genomics Inc. Imidazo[1,2-a] pyrazin-8-ylamines as kinase inhibitors
PE20051046A1 (es) 2003-11-28 2006-01-11 Novartis Ag Derivados de diaril-urea en el tratamiento de enfermedades dependientes de la quinasa de proteina
EP1694691A1 (en) 2003-12-05 2006-08-30 Biovitrum Ab Improved synthesis of 2-substituted adenosines
EP1737463B1 (en) * 2003-12-24 2008-12-03 AstraZeneca AB Pyrimidines with tie2 (tek) activity
DE602004015509D1 (de) * 2003-12-24 2008-09-11 Astrazeneca Ab Pyrimidine mit tie2 (tek) aktivität
AR049769A1 (es) 2004-01-22 2006-09-06 Novartis Ag Derivados de pirazolo(1,5-a)pirimidin 7-il-amina para utilizarse en el tratamiento de enfermedades dependientes de la quinasa de proteina
WO2005097773A1 (en) * 2004-04-07 2005-10-20 Applied Research Systems Ars Holding N.V. 1,1’-(1,2-ethynediyl)bis-benzene derivatives as ptp 1-b inhibitors
DE102004021716A1 (de) 2004-04-30 2005-12-01 Grünenthal GmbH Substituierte Imidazo[1,2-a]pyridin-Verbindungen und Arzneimittel enthaltend substituierte Imidazo[1,2-a]pyridin-Verbindungen
MX2007000481A (es) * 2004-07-14 2007-03-29 Ptc Therapeutics Inc Metodos para tratar hepatitis c.
US7776869B2 (en) * 2004-10-18 2010-08-17 Amgen Inc. Heteroaryl-substituted alkyne compounds and method of use
GB0502418D0 (en) 2005-02-05 2005-03-16 Astrazeneca Ab Compounds
DE602006012815D1 (de) * 2005-03-23 2010-04-22 Hoffmann La Roche Acetylenylpyrazolopyrimidinderivate als mglur2-antagonsten
WO2006103449A2 (en) 2005-03-31 2006-10-05 Astrazeneca Ab Saminopyrimidine derivates with tie2 inhibiting activity
WO2007013673A1 (en) 2005-07-29 2007-02-01 Astellas Pharma Inc. Fused heterocycles as lck inhibitors
WO2007021937A2 (en) 2005-08-11 2007-02-22 Ariad Pharmaceuticals, Inc. Unsaturated heterocyclic derivatives
CA2634923C (en) * 2005-12-23 2015-05-05 Ariad Pharmaceuticals, Inc. Acetylenic bicyclic heteroaryl compounds useful as kinase inhibitors
CN101389338B (zh) * 2005-12-23 2013-06-26 阿里亚德医药股份有限公司 双环杂芳基化合物
AU2007249924B2 (en) 2006-05-08 2013-07-04 Ariad Pharmaceuticals, Inc. Acetylenic heteroaryl compounds
KR101441365B1 (ko) * 2006-05-08 2014-09-18 어리어드 파마슈티칼스, 인코포레이티드 모노시클릭 헤테로아릴 화합물
EP2107054A1 (en) 2008-04-01 2009-10-07 Università Degli Studi Di Milano - Bicocca Antiproliferative compounds and therapeutic uses thereof
WO2010124047A1 (en) 2009-04-23 2010-10-28 Wyeth Llc Bisaryl alkynylamides as negative allosteric modulators of metabotropic glutamate receptor 5 (mglur5)
US8461851B2 (en) 2009-06-08 2013-06-11 University Of Hawaii Systems for transverse electromagnetic mode in-situ soil testing
US8329724B2 (en) 2009-08-03 2012-12-11 Hoffmann-La Roche Inc. Process for the manufacture of pharmaceutically active compounds
AU2010313152A1 (en) 2009-10-30 2012-04-19 Ariad Pharmaceuticals, Inc. Methods and compositions for treating cancer
US20140045826A1 (en) 2011-04-07 2014-02-13 Ariad Pharmaceuticals, Inc. Methods and compositions for treating neurodegenerative diseases
JP5300939B2 (ja) * 2011-08-25 2013-09-25 安田工業株式会社 仕上加工用工具を用いた加工方法
CA3167093A1 (en) 2012-12-12 2014-06-12 Ariad Pharmaceuticals, Inc. Crystalline form c of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-n-{4-[(4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl}benzamide mono hydrochloride

Also Published As

Publication number Publication date
JP2015147796A (ja) 2015-08-20
US20070191376A1 (en) 2007-08-16
HUS1300078I1 (hu) 2018-11-28
ES2403206T3 (es) 2013-05-16
EP3417912B1 (en) 2020-08-12
US20190031656A1 (en) 2019-01-31
EP2495016B1 (en) 2019-10-16
FR13C0069I1 (fr) 2014-01-17
EP1973545A4 (en) 2010-03-10
EA027573B1 (ru) 2017-08-31
US20200231588A1 (en) 2020-07-23
US20160368917A1 (en) 2016-12-22
LT2495016T (lt) 2020-02-10
JP6604739B2 (ja) 2019-11-13
US20140288082A1 (en) 2014-09-25
US9029533B2 (en) 2015-05-12
CY1122646T1 (el) 2020-10-14
PL1973545T3 (pl) 2013-05-31
CN103044432B (zh) 2016-08-03
HUE047422T2 (hu) 2020-04-28
LU92327I9 (es) 2019-01-16
MX343042B (es) 2016-10-21
US20120135986A1 (en) 2012-05-31
EP1973545B1 (en) 2013-01-30
KR20080081191A (ko) 2008-09-08
JP2009521462A (ja) 2009-06-04
CA2634923A1 (en) 2007-07-05
US8470851B2 (en) 2013-06-25
ES2761180T3 (es) 2020-05-19
US20250361232A1 (en) 2025-11-27
KR101436303B1 (ko) 2014-09-02
EP3747441A1 (en) 2020-12-09
IL239445A (en) 2017-02-28
DK2495016T3 (da) 2019-12-16
CN103044432A (zh) 2013-04-17
US20130196979A1 (en) 2013-08-01
PT2495016T (pt) 2019-12-16
LU92327I2 (fr) 2014-02-05
CY2013044I1 (el) 2015-11-04
EP1973545A2 (en) 2008-10-01
US9278971B2 (en) 2016-03-08
JP5790629B2 (ja) 2015-10-07
US20130231337A1 (en) 2013-09-05
AU2006331673A1 (en) 2007-07-05
US8778942B2 (en) 2014-07-15
PL2495016T3 (pl) 2020-06-01
IL191938A0 (en) 2009-08-03
PT1973545E (pt) 2013-02-11
AU2006331673B2 (en) 2013-02-28
EA200870116A1 (ru) 2009-10-30
US8114874B2 (en) 2012-02-14
IL239445A0 (en) 2015-07-30
SI2495016T1 (sl) 2020-04-30
FR13C0069I2 (fr) 2014-04-18
DK1973545T3 (da) 2013-02-25
JP2013064004A (ja) 2013-04-11
CY1113907T1 (el) 2015-11-04
WO2007075869A2 (en) 2007-07-05
EP3417912A1 (en) 2018-12-26
EP2495016A1 (en) 2012-09-05
EA034598B1 (ru) 2020-02-25
JP5200939B2 (ja) 2013-06-05
BRPI0621098A2 (pt) 2013-04-02
CY2013044I2 (el) 2015-11-04
US20220081440A1 (en) 2022-03-17
EA201790678A1 (ru) 2017-12-29
WO2007075869A3 (en) 2007-11-29
CA2634923C (en) 2015-05-05
IL191938A (en) 2016-03-31

Similar Documents

Publication Publication Date Title
MX2008008152A (es) Compuestos heterociclicos biciclicos.
WO2007133560A3 (en) Acetylenic heteroaryl compounds
TW200800968A (en) Sulfoximine-substituted pyrimidines, processes for production thereof and use thereof as drugs
AU2007249926A8 (en) Monocyclic heteroaryl compounds
WO2007021937A3 (en) Unsaturated heterocyclic derivatives
WO2010077740A3 (en) Novel antiviral compounds, compositions, and methods of use
PH12012501346A1 (en) Heteroaryl compounds and uses thereof
WO2009043889A3 (en) Oxadiazole derivatives
WO2009156462A3 (en) Organic compounds
TW200801003A (en) Novel compounds
TW200635938A (en) Fluorosurfactants
EP1919302B8 (en) Food comprising silicon
WO2010068292A8 (en) Azaindole derivatives as kinase inhibitors
WO2009077471A3 (de) Azolylmethyloxirane, ihre verwendung sowie sie enthaltende mittel
MX2011014019A (es) Derivados de diazahomoadamantano y sus metodos de uso.
WO2007097981A3 (en) Alpha carbolines and uses thereof
EA201070009A1 (ru) Производные 7-алкинил-1,8-нафтиридонов, их получение и их применение в терапии
EA200701707A1 (ru) Пиразолопиримидины
WO2009115084A3 (de) Pyrrolopyrimidin-derivate und deren verwendungen
TW200738659A (en) Novel compounds
MX2009010174A (es) Derivados de aza-adamantano ester y carbamato y metodos de uso de los mismos.
GB0508318D0 (en) Organic compounds
TW200700064A (en) Novel compounds
TW200740814A (en) Compounds
MX2009000768A (es) Lactamas macrociclicas.

Legal Events

Date Code Title Description
FG Grant or registration